公开(公告)号：US20150056655A1

公开(公告)日：2015-02-26

申请号：US14453328

申请日：2014-08-06

申请人： Glenmark Pharmaceuticals S.A.

发明人： Christel AEBISCHER-GUMY ,  Martin Bertschinger ,  Pierre Moretti

IPC分类号： C07K16/46 ,  C12N15/85

CPC分类号： C07K16/468 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/64 ,  C12N15/85 ,  C12N2840/20 ,  C12N2840/445 ,  C12P21/02

摘要： The invention relates to an expression construct for the expression of polypeptides in host cells using alternative splicing. The expression construct can be used for the expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies by expressing the gene products required for protein expression at the ratio leading to the highest titres or the best product quality profile.

摘要翻译： 本发明涉及使用选择性剪接在宿主细胞中表达多肽的表达构建体。 通过以导致最高滴度或最佳产品质量分布的比例表达蛋白质表达所需的基因产物，表达构建体可用于表达多肽，例如抗体，抗体片段和双特异性抗体。

公开(公告)号：US20140364445A1

公开(公告)日：2014-12-11

申请号：US14362003

申请日：2012-12-05

申请人： GLENMARK PHARMACEUTICALS S.A.

发明人： Neelima Khairatkar-Joshi ,  Raghuram Anupindi ,  Selvan Vaiyapuri Thamil ,  Abhay Kulkarni ,  Amol Waghchoure

IPC分类号： A61K31/519 ,  A61K31/439

CPC分类号： A61K31/519 ,  A61K31/40 ,  A61K31/407 ,  A61K31/41 ,  A61K31/429 ,  A61K31/439 ,  A61K31/46 ,  A61K31/47 ,  A61K31/4985 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and an anticholinergic agent. Particularly, the present invention provides a pharmaceutical composition comprising a TRPA1 antagonist having IC50 for inhibiting human TRPA1 receptor activity of less than 1 micromolar and an anticholinergic agent; a process for preparing such composition; and its use in treating a respiratory disorder in a subject.

摘要翻译： 本发明涉及包含瞬时受体电位锚蛋白-1受体（“TRPA1”）拮抗剂和抗胆碱能剂的药物组合物。 特别地，本发明提供一种药物组合物，其包含具有抑制小于1微摩尔的人TRPA1受体活性的IC50和抗胆碱能药物的TRPA1拮抗剂; 制备这种组合物的方法; 及其用于治疗受试者的呼吸系统疾病。

公开(公告)号：US08889862B2

公开(公告)日：2014-11-18

申请号：US14058509

申请日：2013-10-21

申请人： Glenmark Pharmaceuticals, S.A.

发明人： Sukeerthi Kumar ,  Abraham Thomas ,  Sachin Sundarlal Chaudhari ,  Bipin Parsottam Kansagra ,  Venkata Ramana Yemireddy ,  Neelima Khairatkar-Joshi ,  Indranil Mukhopadhyay ,  Girish Gudi

IPC分类号： C07D491/00 ,  C07D211/60 ,  C07D277/00 ,  A61K31/519 ,  A61K31/445 ,  A61K31/425 ,  C07D513/04 ,  C07D491/048 ,  C07D495/04 ,  C07D491/04 ,  C07F9/6561 ,  C07D487/04

CPC分类号： C07F9/6561 ,  C07D487/04 ,  C07D491/04 ,  C07D491/048 ,  C07D495/04 ,  C07D513/04 ,  C07F9/65616

摘要： The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

摘要翻译： 本发明涉及作为TRPA（瞬时受体电位亚族A）调节剂的2-氨基-4-芳基噻唑衍生物。 特别地，本文所述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚科A，成员1）调节的疾病，病症和/或病症。 本文还提供了制备本文所述化合物的方法，其合成中使用的中间体，其药物组合物，以及用于治疗或预防由TRPA1调节的疾病，病症和/或障碍的方法。

公开(公告)号：US20130289054A1

公开(公告)日：2013-10-31

申请号：US13925975

申请日：2013-06-25

申请人： Glenmark Pharmaceuticals S.A.

发明人： Sukeerthi Kumar ,  Abraham Thomas ,  Nayan Taterao Waghmare ,  Sanjay Margal ,  Neelima Khairatkar-Joshi ,  Indranil Mukhopadhyay

IPC分类号： C07D495/04

CPC分类号： A61K31/519 ,  A61K45/06 ,  C07D495/04

摘要： The present invention is related to novel thienopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.